Table 2.
Outcomes of patients before PSM.
| Variable a | No anticoagulation, N = 430 (66%) | Anticoagulation, N = 223 (34%) | p-value b |
|---|---|---|---|
| TICI 2c-3, n (%) | 233 (57) | 121 (57) | >0.99 |
| TICI 2b-3, n (%) | 350 (85) | 183 (86) | 0.85 |
| FPE, n (%) | 131 (34) | 73 (35) | 0.94 |
| 90-day mRS 0–1, n (%) | 159 (37) | 68 (30) | 0.1 |
| 90-day mRS 0–2, n (%) | 217 (50) | 105 (47) | 0.41 |
| 90-day mortality, n (%) | 74 (17) | 58 (26) | 0.008 |
| Intracranial hemorrhage (any type), n (%) | 155 (36) | 77 (35) | 0.7 |
| Intracranial hemorrhage (by type), n (%) | |||
| HI1 | 70 (16) | 27 (12) | 0.16 |
| HI2 | 12 (2.8) | 5 (2.3) | 0.68 |
| PH1 | 15 (3.5) | 8 (3.6) | 0.94 |
| PH2 | 12 (2.8) | 6 (2.7) | 0.94 |
| SAH | 41 (9.6) | 28 (13) | 0.23 |
| Embolization in new territories, n (%) | 16 (3.8) | 9 (4.1) | 0.86 |
| Perforation, n (%) | 15 (3.6) | 8 (3.7) | 0.96 |
a
TICI: thrombolysis in cerebral infarction; FPE: first-pass effect; HI1: hemorrhagic infarction type 1; HI2: hemorrhagic infarction type 2; PH1: parenchymal hemorrhage type 1; PH2: parenchymal hemorrhage type 2; SAH: subarachnoid hemorrhage.
b
Pearson’s chi-squared test; Wilcoxon rank sum test; Fisher’s exact test.